查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1193077

脂肪團治療市場：按手術類型、脂肪團類型、最終用戶分類：2021-2031 年全球機會分析和行業預測

Cellulite Treatment Market By Procedure Type, By Cellulite Type, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 290 Pages | 商品交期: 2-3個工作天內

價格

全球脂肪團治療市場預計到 2021 年將達到 21.4 億美元，到 2031 年將達到 57.29 億美元，2022 年至 2031 年的複合年增長率為 10.3%。.

橘皮組織是纖維結締組織內皮下脂肪的突出，在皮膚上表現為酒窩或結節，最常見於骨盆（尤其是臀部）、下肢和腹部。 這種症狀在女性中更為常見。

快餐消費和久坐不動的生活方式導致肥胖率上升正在推動市場增長。 脂肪團的形成與體重增加和高脂肪有關。 美容程序的增加和美容診所的增加也促進了市場的增長。 例如，根據國際美容整形外科學會 (ISAPS) 的一項研究，2020 年全球將進行約 10,129,528 例整容手術。 由於社交媒體的影響和名人在年輕一代中的流行，男性和女性對迷人外表的需求越來越大，並且有動力看起來美觀，為市場增長創造了充足的機會。 橘皮組織治療可減少脂肪沉積，尤其是大腿和臀部周圍的脂肪沉積，進一步改善外觀。

對微創整容手術的需求不斷增長、整容手術越來越受歡迎以及遺傳因素（主要是女性）正在推動市場增長。 對先進的非侵入性脂肪團治療的認識不斷提高，整容外科醫生數量激增預計將在未來幾年推動市場增長。

此外，主要參與者在市場上增加高級橘皮組織治療開發、產品批准和新產品發布的研發活動將促進市場增長。 例如，2020 年 7 月，高度專注的專業品牌和仿製藥公司 Endo International plc 宣布其用於治療成年女性臀部中度至重度脂肪團的 Qwo（膠原□溶組織梭菌-aaes）已獲得批准由美國食品和藥物管理局 (FDA) 提供。 然而，新興國家先進脂肪團治療的高成本和不發達的醫療基礎設施可能會阻礙市場增長。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章脂肪團治療市場：按治療類型分類

  • 概覽
    • 市場規模和預測
  • 非侵入性
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 微創
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 局部麻醉
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章脂肪團治療市場：按脂肪團類型

  • 概覽
    • 市場規模和預測
  • 柔軟的橘皮組織
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
    • 軟脂肪團/脂肪團治療市場：性別
      • 男裝市場規模和預測：按地區
      • 女性市場規模和預測：按地區
  • 硬脂肪團
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
    • 硬脂肪團的脂肪團治療市場：性別
      • 男裝市場規模和預測：按地區
      • 女性市場規模的變化和預測：按地區
  • 水腫
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章脂肪團治療市場：最終用戶

  • 概覽
    • 市場規模和預測
  • 醫院
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 診所、美容中心
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 7 章脂肪治療市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測：按治療類型
    • 北美市場規模和預測：按橘皮組織類型
      • 北美軟脂肪團/脂肪團治療市場：性別
      • 北美硬脂肪團/脂肪團治療市場：性別
    • 北美市場規模和預測：按最終用戶分類
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按治療類型分類
    • 歐洲市場規模和預測：按橘皮組織類型
      • 歐洲軟脂肪團/脂肪團治療市場：性別
      • 歐洲硬脂肪團/橘皮組織治療市場：性別
    • 歐洲市場規模和預測：按最終用戶分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機會
    • 亞太地區的市場規模和預測：按治療類型
    • 亞太市場規模和預測：按橘皮組織類型
      • 亞太地區軟脂肪團和脂肪團治療市場：按性別
      • 亞太地區剛性脂肪團和橘皮組織治療市場：按性別分類
    • 亞太市場規模和預測：按最終用戶分類
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機會
    • LAMEA 市場規模和預測：按治療類型
    • LAMEA 市場規模和預測：按橘皮組織類型
      • LAMEA 軟脂肪團和脂肪團治療市場：按性別分類
      • LAMEA 硬脂肪團/脂肪團治療市場：按性別分類
    • LAMEA 市場規模和預測：按最終用戶分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其餘部分

第八章公司情況

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第九章公司簡介

  • Abbvie Inc
  • Candela Syneron
  • Cynosure Technologies
  • Merz Pharma GmbH & Co. KGaA
  • Bausch Health Companies Inc.
  • Hologic Inc
  • Zimmer Aesthetics
  • Galderma SA
  • Sinclair Pharmaceuticals Limited
  • Endo International plc
Product Code: A10923

The global cellulite treatment market was valued at $2,140.0 million in 2021, and is projected to reach $5,729.06 million by 2031, registering a CAGR of 10.3% from 2022 to 2031.

Cellulite is the herniation of subcutaneous fat within fibrous connective tissue that manifests as skin dimpling and nodularity, often on the pelvic region (specifically the buttocks), lower limbs, and abdomen. The condition is most prevalent in women.

The increase in obesity rate owing to fast food consumption and sedentary lifestyle drive the growth of the market. Weight gain and high obesity are responsible for the development of cellulites. In addition, the increase in the number of cosmetic procedures and the rise in a number of cosmetic clinics contribute toward the growth of the market. For instance, according to International Society of Aesthetic Plastic Surgery (ISAPS) survey, in 2020 about 10,129,528 cosmetic surgical procedures are carried worldwide. The rise in demand for attractive physical appearance in men and women owing to social media influence and celebrities who are popular among the young generation, motivate them to look aesthetically appealing, which provides ample opportunities for market growth. The cellulite treatment, reduces the fat depositions especially from around the thighs and buttocks which further enhances the appearance.

The increase in demand for minimally invasive cosmetic procedures, rise in popularity of cosmetic procedures and genetical factors predominantly in women contribute toward the market growth. Increase in awareness about advanced non-invasive cellulite treatment, and surge in number of cosmetology surgeons are expected to drive the market growth in the coming years.

Moreover, the increase in R&D activities for development of advanced cellulite treatment, product approvals and novel product launch in the market by key players boost the market growth. For instance, in July 2020, Endo International plc, a highly-focused specialty branded and generics pharmaceutical company, has received U.S. Food and Drug Administration (FDA) approval for its, Qwo (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women. However, the high cost of advanced cellulite treatment and underdeveloped health care infrastructure in developing countries may hinder the growth of the market.

The cellulite treatment market is segmented on the basis of procedure type, cellulite type, end user and region. By procedure type, the market is divided into non-invasive, minimal invasive and topical. By cellulite type, the market is classified into soft cellulite, hard cellulite, and edematous cellulite. The soft cellulite segment is further divided into male and female. The hard cellulite segment is further bifurcated into male and female. By end user, the market is categorized into hospitals, clinics & beauty centers, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include ABBVIE, Bausch Health Companies Inc, Candela Syneron, Cynosure, Galderma SA, Johnson & Johnson, Merz Pharma GmbH & Co. KGaA, Sientra Inc, Sinclair Pharma and Teoxane Laboratories.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cellulite treatment market analysis from 2021 to 2031 to identify the prevailing cellulite treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cellulite treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cellulite treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Procedure Type

  • Non-invasive
  • Minimally Invasive
  • Topical

By Cellulite Type

  • Soft Cellulite
    • Gender
    • Male
    • Female
  • Hard Cellulite
    • Gender
    • Male
    • Female
  • Edematous

By End User

  • Hospitals
  • Clinics and Beauty Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Abbvie Inc
    • Candela Syneron
    • Cynosure Technologies
    • Merz Pharma GmbH & Co. KGaA
    • Bausch Health Companies Inc.
    • Hologic Inc
    • Zimmer Aesthetics
    • Galderma SA
    • Sinclair Pharmaceuticals Limited
    • Endo International plc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Non-invasive
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Minimally Invasive
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Topical
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: CELLULITE TREATMENT MARKET, BY CELLULITE TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Soft Cellulite
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
    • 5.2.4 Soft Cellulite Cellulite Treatment Market by Gender
      • 5.2.4.1 Male Market size and forecast, by region
      • 5.2.4.2 Female Market size and forecast, by region
  • 5.3 Hard Cellulite
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
    • 5.3.4 Hard Cellulite Cellulite Treatment Market by Gender
      • 5.3.4.1 Male Market size and forecast, by region
      • 5.3.4.2 Female Market size and forecast, by region
  • 5.4 Edematous
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: CELLULITE TREATMENT MARKET, BY END USER

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Clinics and Beauty Centers
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Others
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: CELLULITE TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Procedure Type
    • 7.2.3 North America Market size and forecast, by Cellulite Type
      • 7.2.3.1 North America Soft Cellulite Cellulite Treatment Market by Gender
      • 7.2.3.2 North America Hard Cellulite Cellulite Treatment Market by Gender
    • 7.2.4 North America Market size and forecast, by End User
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Procedure Type
      • 7.2.5.1.2 Market size and forecast, by Cellulite Type
      • 7.2.5.1.3 Market size and forecast, by End User
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Procedure Type
      • 7.2.5.2.2 Market size and forecast, by Cellulite Type
      • 7.2.5.2.3 Market size and forecast, by End User
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Procedure Type
      • 7.2.5.3.2 Market size and forecast, by Cellulite Type
      • 7.2.5.3.3 Market size and forecast, by End User
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Procedure Type
    • 7.3.3 Europe Market size and forecast, by Cellulite Type
      • 7.3.3.1 Europe Soft Cellulite Cellulite Treatment Market by Gender
      • 7.3.3.2 Europe Hard Cellulite Cellulite Treatment Market by Gender
    • 7.3.4 Europe Market size and forecast, by End User
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Procedure Type
      • 7.3.5.1.2 Market size and forecast, by Cellulite Type
      • 7.3.5.1.3 Market size and forecast, by End User
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Procedure Type
      • 7.3.5.2.2 Market size and forecast, by Cellulite Type
      • 7.3.5.2.3 Market size and forecast, by End User
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Procedure Type
      • 7.3.5.3.2 Market size and forecast, by Cellulite Type
      • 7.3.5.3.3 Market size and forecast, by End User
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Procedure Type
      • 7.3.5.4.2 Market size and forecast, by Cellulite Type
      • 7.3.5.4.3 Market size and forecast, by End User
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Procedure Type
      • 7.3.5.5.2 Market size and forecast, by Cellulite Type
      • 7.3.5.5.3 Market size and forecast, by End User
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Procedure Type
      • 7.3.5.6.2 Market size and forecast, by Cellulite Type
      • 7.3.5.6.3 Market size and forecast, by End User
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Procedure Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Cellulite Type
      • 7.4.3.1 Asia-Pacific Soft Cellulite Cellulite Treatment Market by Gender
      • 7.4.3.2 Asia-Pacific Hard Cellulite Cellulite Treatment Market by Gender
    • 7.4.4 Asia-Pacific Market size and forecast, by End User
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Procedure Type
      • 7.4.5.1.2 Market size and forecast, by Cellulite Type
      • 7.4.5.1.3 Market size and forecast, by End User
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Procedure Type
      • 7.4.5.2.2 Market size and forecast, by Cellulite Type
      • 7.4.5.2.3 Market size and forecast, by End User
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Procedure Type
      • 7.4.5.3.2 Market size and forecast, by Cellulite Type
      • 7.4.5.3.3 Market size and forecast, by End User
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Procedure Type
      • 7.4.5.4.2 Market size and forecast, by Cellulite Type
      • 7.4.5.4.3 Market size and forecast, by End User
      • 7.4.5.5 Rest of Asia-Pacific
      • 7.4.5.5.1 Market size and forecast, by Procedure Type
      • 7.4.5.5.2 Market size and forecast, by Cellulite Type
      • 7.4.5.5.3 Market size and forecast, by End User
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Procedure Type
    • 7.5.3 LAMEA Market size and forecast, by Cellulite Type
      • 7.5.3.1 LAMEA Soft Cellulite Cellulite Treatment Market by Gender
      • 7.5.3.2 LAMEA Hard Cellulite Cellulite Treatment Market by Gender
    • 7.5.4 LAMEA Market size and forecast, by End User
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Procedure Type
      • 7.5.5.1.2 Market size and forecast, by Cellulite Type
      • 7.5.5.1.3 Market size and forecast, by End User
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Procedure Type
      • 7.5.5.2.2 Market size and forecast, by Cellulite Type
      • 7.5.5.2.3 Market size and forecast, by End User
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Procedure Type
      • 7.5.5.3.2 Market size and forecast, by Cellulite Type
      • 7.5.5.3.3 Market size and forecast, by End User
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Procedure Type
      • 7.5.5.4.2 Market size and forecast, by Cellulite Type
      • 7.5.5.4.3 Market size and forecast, by End User

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Abbvie Inc
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Candela Syneron
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Cynosure Technologies
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Merz Pharma GmbH & Co. KGaA
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Bausch Health Companies Inc.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Hologic Inc
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Zimmer Aesthetics
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Galderma SA
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Sinclair Pharmaceuticals Limited
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Endo International plc
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 2. CELLULITE TREATMENT MARKET, FOR NON-INVASIVE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. CELLULITE TREATMENT MARKET FOR NON-INVASIVE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. CELLULITE TREATMENT MARKET, FOR MINIMALLY INVASIVE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. CELLULITE TREATMENT MARKET FOR MINIMALLY INVASIVE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. CELLULITE TREATMENT MARKET, FOR TOPICAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. CELLULITE TREATMENT MARKET FOR TOPICAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. GLOBAL CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 9. CELLULITE TREATMENT MARKET, FOR SOFT CELLULITE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. CELLULITE TREATMENT MARKET FOR SOFT CELLULITE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. GLOBAL SOFT CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 12. CELLULITE TREATMENT MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. CELLULITE TREATMENT MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. CELLULITE TREATMENT MARKET, FOR HARD CELLULITE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. CELLULITE TREATMENT MARKET FOR HARD CELLULITE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. GLOBAL HARD CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 17. CELLULITE TREATMENT MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. CELLULITE TREATMENT MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 19. CELLULITE TREATMENT MARKET, FOR EDEMATOUS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. CELLULITE TREATMENT MARKET FOR EDEMATOUS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. GLOBAL CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 22. CELLULITE TREATMENT MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 23. CELLULITE TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 24. CELLULITE TREATMENT MARKET, FOR CLINICS AND BEAUTY CENTERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. CELLULITE TREATMENT MARKET FOR CLINICS AND BEAUTY CENTERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. CELLULITE TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. CELLULITE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 28. CELLULITE TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 31. NORTH AMERICA SOFT CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 32. NORTH AMERICA HARD CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 33. NORTH AMERICA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 34. NORTH AMERICA CELLULITE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 35. U.S. CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 36. U.S. CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 37. U.S. CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 38. CANADA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 39. CANADA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 40. CANADA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 41. MEXICO CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 42. MEXICO CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 43. MEXICO CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 44. EUROPE CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 45. EUROPE CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 46. EUROPE SOFT CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 47. EUROPE HARD CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 48. EUROPE CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 49. EUROPE CELLULITE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 50. GERMANY CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 51. GERMANY CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 52. GERMANY CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 53. FRANCE CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 54. FRANCE CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 55. FRANCE CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 56. UK CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 57. UK CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 58. UK CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 59. ITALY CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 60. ITALY CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 61. ITALY CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 62. SPAIN CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 63. SPAIN CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 64. SPAIN CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 65. REST OF EUROPE CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 66. REST OF EUROPE CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 67. REST OF EUROPE CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 68. ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 69. ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 70. ASIA-PACIFIC SOFT CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 71. ASIA-PACIFIC HARD CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 72. ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 73. ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 74. JAPAN CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 75. JAPAN CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 76. JAPAN CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 77. CHINA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 78. CHINA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 79. CHINA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 80. AUSTRALIA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 81. AUSTRALIA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 82. AUSTRALIA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 83. INDIA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 84. INDIA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 85. INDIA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 86. REST OF ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 87. REST OF ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 88. REST OF ASIA-PACIFIC CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 89. LAMEA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 90. LAMEA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 91. LAMEA SOFT CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 92. LAMEA HARD CELLULITE CELLULITE TREATMENT MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 93. LAMEA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 94. LAMEA CELLULITE TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 95. BRAZIL CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 96. BRAZIL CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 97. BRAZIL CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 98. SAUDI ARABIA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 99. SAUDI ARABIA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 100. SAUDI ARABIA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 101. SOUTH AFRICA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 102. SOUTH AFRICA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 103. SOUTH AFRICA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 104. REST OF LAMEA CELLULITE TREATMENT MARKET, BY PROCEDURE TYPE, 2021-2031 ($MILLION)
  • TABLE 105. REST OF LAMEA CELLULITE TREATMENT MARKET, BY CELLULITE TYPE, 2021-2031 ($MILLION)
  • TABLE 106. REST OF LAMEA CELLULITE TREATMENT MARKET, BY END USER, 2021-2031 ($MILLION)
  • TABLE 107.ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 108.ABBVIE INC: OPERATING SEGMENTS
  • TABLE 109.ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 110.ABBVIE INC: NET SALES,
  • TABLE 111.ABBVIE INC: KEY STRATERGIES
  • TABLE 112.CANDELA SYNERON: COMPANY SNAPSHOT
  • TABLE 113.CANDELA SYNERON: OPERATING SEGMENTS
  • TABLE 114.CANDELA SYNERON: PRODUCT PORTFOLIO
  • TABLE 115.CANDELA SYNERON: NET SALES,
  • TABLE 116.CANDELA SYNERON: KEY STRATERGIES
  • TABLE 117.CYNOSURE TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 118.CYNOSURE TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 119.CYNOSURE TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 120.CYNOSURE TECHNOLOGIES: NET SALES,
  • TABLE 121.CYNOSURE TECHNOLOGIES: KEY STRATERGIES
  • TABLE 122.MERZ PHARMA GMBH & CO. KGAA: COMPANY SNAPSHOT
  • TABLE 123.MERZ PHARMA GMBH & CO. KGAA: OPERATING SEGMENTS
  • TABLE 124.MERZ PHARMA GMBH & CO. KGAA: PRODUCT PORTFOLIO
  • TABLE 125.MERZ PHARMA GMBH & CO. KGAA: NET SALES,
  • TABLE 126.MERZ PHARMA GMBH & CO. KGAA: KEY STRATERGIES
  • TABLE 127.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 128.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
  • TABLE 129.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 130.BAUSCH HEALTH COMPANIES INC.: NET SALES,
  • TABLE 131.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
  • TABLE 132.HOLOGIC INC: COMPANY SNAPSHOT
  • TABLE 133.HOLOGIC INC: OPERATING SEGMENTS
  • TABLE 134.HOLOGIC INC: PRODUCT PORTFOLIO
  • TABLE 135.HOLOGIC INC: NET SALES,
  • TABLE 136.HOLOGIC INC: KEY STRATERGIES
  • TABLE 137.ZIMMER AESTHETICS: COMPANY SNAPSHOT
  • TABLE 138.ZIMMER AESTHETICS: OPERATING SEGMENTS
  • TABLE 139.ZIMMER AESTHETICS: PRODUCT PORTFOLIO
  • TABLE 140.ZIMMER AESTHETICS: NET SALES,
  • TABLE 141.ZIMMER AESTHETICS: KEY STRATERGIES
  • TABLE 142.GALDERMA SA: COMPANY SNAPSHOT
  • TABLE 143.GALDERMA SA: OPERATING SEGMENTS
  • TABLE 144.GALDERMA SA: PRODUCT PORTFOLIO
  • TABLE 145.GALDERMA SA: NET SALES,
  • TABLE 146.GALDERMA SA: KEY STRATERGIES
  • TABLE 147.SINCLAIR PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
  • TABLE 148.SINCLAIR PHARMACEUTICALS LIMITED: OPERATING SEGMENTS
  • TABLE 149.SINCLAIR PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
  • TABLE 150.SINCLAIR PHARMACEUTICALS LIMITED: NET SALES,
  • TABLE 151.SINCLAIR PHARMACEUTICALS LIMITED: KEY STRATERGIES
  • TABLE 152.ENDO INTERNATIONAL PLC: COMPANY SNAPSHOT
  • TABLE 153.ENDO INTERNATIONAL PLC: OPERATING SEGMENTS
  • TABLE 154.ENDO INTERNATIONAL PLC: PRODUCT PORTFOLIO
  • TABLE 155.ENDO INTERNATIONAL PLC: NET SALES,
  • TABLE 156.ENDO INTERNATIONAL PLC: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.CELLULITE TREATMENT MARKET SEGMENTATION
  • FIGURE 2.CELLULITE TREATMENT MARKET,2021-2031
  • FIGURE 3.CELLULITE TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.CELLULITE TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.CELLULITE TREATMENT MARKET,BY PROCEDURE TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF NON-INVASIVE CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MINIMALLY INVASIVE CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF TOPICAL CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.CELLULITE TREATMENT MARKET,BY CELLULITE TYPE,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF SOFT CELLULITE CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF HARD CELLULITE CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF EDEMATOUS CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.CELLULITE TREATMENT MARKET,BY END USER,2021(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITALS CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF CLINICS AND BEAUTY CENTERS CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHERS CELLULITE TREATMENT MARKET,2021-2031(%)
  • FIGURE 24.CELLULITE TREATMENT MARKET BY REGION,2021
  • FIGURE 25.U.S. CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 26.CANADA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.MEXICO CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.GERMANY CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.FRANCE CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.UK CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.ITALY CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.SPAIN CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.REST OF EUROPE CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.JAPAN CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.CHINA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.AUSTRALIA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.INDIA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.REST OF ASIA-PACIFIC CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.BRAZIL CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.SAUDI ARABIA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.SOUTH AFRICA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.REST OF LAMEA CELLULITE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47.COMPETITIVE DASHBOARD
  • FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 49.ABBVIE INC.: NET SALES ,($MILLION)
  • FIGURE 50.CANDELA SYNERON.: NET SALES ,($MILLION)
  • FIGURE 51.CYNOSURE TECHNOLOGIES.: NET SALES ,($MILLION)
  • FIGURE 52.MERZ PHARMA GMBH & CO. KGAA.: NET SALES ,($MILLION)
  • FIGURE 53.BAUSCH HEALTH COMPANIES INC..: NET SALES ,($MILLION)
  • FIGURE 54.HOLOGIC INC.: NET SALES ,($MILLION)
  • FIGURE 55.ZIMMER AESTHETICS.: NET SALES ,($MILLION)
  • FIGURE 56.GALDERMA SA.: NET SALES ,($MILLION)
  • FIGURE 57.SINCLAIR PHARMACEUTICALS LIMITED.: NET SALES ,($MILLION)
  • FIGURE 58.ENDO INTERNATIONAL PLC.: NET SALES ,($MILLION)